vTv Therapeutics IncNASDAQ:VTVT
- LAST PRICE14.1800
- TODAY'S CHANGE (%)-0.6500 (-4.3830%)
- Bid / Lots11.3700/ 1
- Ask / Lots22.6800/ 13
- Open / Previous Close14.6500 / 14.8300
- Day Range
- 52 Week Range
- Volume6,909
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTVT |
|---|---|---|
| 09:32 ET | 218 | 14.65 |
| 12:12 ET | 639 | 14.65 |
| 12:37 ET | 100 | 14.6 |
| 12:48 ET | 100 | 14.81 |
| 02:14 ET | 250 | 15.195 |
| 03:15 ET | 1181 | 14.8101 |
| 03:35 ET | 100 | 14.57 |
| 03:55 ET | 400 | 14.405 |
| 04:00 ET | 964 | 14.18 |
Nov 12, 2024
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ vTv Therapeutics 3Q Loss/Shr 88c >VTVT, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Oct 25, 2024
DJ VTv, OnKure Terminate Cellular Drug Licensing Agreement, from 5:41PM ET on Friday Oct 25, 2024 by Dow Jones
5:41PM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
vTv Therapeutics Inc | 42.7M | -3.2x | --- |
Rallybio Corp | 42.3M | -0.6x | --- |
Achilles Therapeutics PLC | 43.6M | -0.6x | --- |
Iterum Therapeutics PLC | 41.1M | -0.9x | --- |
OKYO Pharma Ltd | 35.5M | -1.5x | --- |
Gain Therapeutics Inc | 44.7M | -1.5x | --- |
Company Information
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Contact Information
- Headquarters
- 3980 Premier Dr, Suite 310HIGH POINT, NC, United States 27265
- Phone
- 336-841-0300
- Fax
- 336-841-0310
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Sekhri
- Chief Financial Officer, Executive Vice President
- Steven Tuch
- Executive Vice President - Corporate Development, Director
- Richard Nelson
- Independent Director
- Srinivas Akkaraju
- Independent Director
- Fahed Al Marzooqi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.7M |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-4.42 |
Book Value | $-9.27 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 42.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,399.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
